Rutherford C
J Intraven Nurs. 1991 May-Jun;14(3):163-5.
After more than 25 years of research and technology, a new product has recently been developed for the treatment of anemia associated with chronic renal failure in dialysis-dependent patients with end-stage renal disease. The availability of erythropoietin offers several advantages over other forms of treatment, such as red blood cell transfusions and androgens. This article describes the composition of erythropoietin, administration techniques, considerations for dosing, patient monitoring criteria, and patient education for those who receive it.
经过25年多的研究与技术探索，最近研发出了一种新产品，用于治疗终末期肾病依赖透析的患者中与慢性肾衰竭相关的贫血。与其他治疗方式（如红细胞输血和雄激素）相比，促红细胞生成素的应用具有若干优势。本文介绍了促红细胞生成素的成分、给药技术、剂量考量、患者监测标准以及接受该治疗的患者教育内容。
